Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) reports on events occurring on July 8, 2019, and July 11, 2019. The filing addresses significant changes in the company's executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Manmeet S. Soni resigned as Senior Vice President, CFO, principal financial officer, and principal accounting officer. His resignation is effective August 12, 2019.
- Appointment of New CFO: Jeffrey Poulton was appointed to succeed Mr. Soni as Executive Vice President and CFO, effective August 13, 2019. He will also serve as the designated principal financial and accounting officer for SEC reporting purposes.
Management Commentary, Risks, and Unusual Items
Separation Agreement (Mr. Soni)
Mr. Soni entered into a Separation Agreement dated July 10, 2019. Key terms include:
- Twelve months of salary continuation.
- COBRA premium coverage until the earlier of February 28, 2021, or eligibility for other coverage.
- Continued vesting of equity awards through a consulting period ending August 12, 2020, contingent on providing up to ten hours of consulting per month.
- Equity awards vested at the end of the consulting period will be exercisable through November 12, 2020.
Compensation Package (Mr. Poulton)
Mr. Poulton's compensation package includes:
- Base Salary: $530,000 annually.
- Annual Cash Bonus: Target of 50% of base salary, subject to performance goals.
- Equity Grant: Option to purchase 125,000 shares of common stock. The options have a ten-year term, an exercise price based on the closing price on the grant date, and vest over four years (25% on the first anniversary, with the remainder vesting ratably quarterly).
- Other Agreements: Mr. Poulton will enter into a Change in Control Agreement and an indemnification agreement consistent with existing executive officer forms.
Investor Verification Checklist
- Verify the exact effective dates for the transition of CFO duties (August 12, 2019, for departure; August 13, 2019, for appointment).
- Review the specific vesting schedule and exercise terms for the 125,000 stock options granted to Mr. Poulton.
- Confirm the duration and scope of Mr. Soni's consulting obligations through August 2020.
- Check subsequent filings (e.g., Form 10-Q) for the impact of these personnel changes on financial reporting timelines.